"With 30 patients accompanied with Aeson towards a successful transplant, including 16 since the beginning of the year, our device continues to prove that it has the potential to become a first-line solution to save patients at the increasingly severe stage of the disease," said Stéphane Piat, CEO of Carmat, in a statement.
Of the 30 transplants carried out in 7 different countries, including 16 in France and 5 in Germany, 16 have been performed since the beginning of 2024, the group said.
Carmat is organizing the first "Aeson European User Meeting" at the end of November, where over 100 European experts are expected to share their experience.
(Written by Mara Vîlcu, edited by Kate Entringer)